文献速递心血管技术与安全PETMRCT

¹²⁴I-evuzamitide PET 对心脏淀粉样变的诊断价值

124Iodine Evuzamitide Positron Emission Tomography in Patients With Established or Suspected Cardiac Amyloidosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2026-08-30

本研究为开放标签试验,纳入126例已知或疑似心脏淀粉样变患者,行¹²⁴I-evuzamitide PET/MRI或PET/CT。以左室心肌摄取高于血池为阳性标准,所有CA患者均为阳性、所有非CA患者均为阴性。结果显示该示踪剂诊断CA具有100%敏感度和特异度,且耐受性良好。

要点

  • ¹²⁴I-evuzamitide PET 左室心肌摄取高于血池可高度提示心脏淀粉样变。
  • CA患者左室/血池SUV比值均值1.89±0.29,非CA患者为0.91±0.15。
  • 该检查或可作为排除或确认CA的单一上游评估手段。

核心结论

  • ¹²⁴I-evuzamitide PET 在已知或疑似CA患者中具有极佳诊断准确性,或可提供对CA存在与否的单一上游评估。

研究设计与样本

  • 开放标签试验,连续纳入126例疑似或已知心脏淀粉样变患者,平均年龄71.6±10.6岁,76.2%为男性。
  • 123例采用PET/MRI,3例采用PET/CT,平均注射活度1.05±0.02 mCi。
  • 参考标准为临床诊断,87例(69%)最终诊断为心脏淀粉样变。

关键影像表现/征象

  • 阳性标准为视觉判读左室心肌放射性摄取高于血池活性,由3名专家读片者分别判定。
  • 所有CA患者左室心肌均呈视觉阳性摄取,所有非CA患者均呈视觉阴性。
  • 定量分析中,CA患者左室/血池SUV比值均值1.89±0.29,非CA患者0.91±0.15(P<0.001)。

诊断标准与关键数值

  • 以左室心肌摄取大于血池活性为视觉阳性标准,诊断CA的敏感度为100%,特异度为100%。
  • 5例患者读片者间判读不一致,被归为模棱两可或阴性,Fleiss's kappa=0.94,最终均未诊断CA。
  • 模棱两可扫描预设归类为阴性(读片者间一致性分析除外)。

临床应用与阅片要点

  • 阅片时以左室心肌摄取是否超过血池作为核心判读依据,注意同一患者多读者间可能存在的判读分歧。
  • 该技术基于pan-amyloid示踪剂,非依赖心肌厚度或心功能,可用于疑似或已知CA的排查。
  • PET/MRI为优先选择,PET/CT可作为替代,临床阅片需结合所采用的设备类型判断图像质量。

局限性

  • 研究为开放标签设计,存在潜在的验证偏倚风险。
  • 仅3例采用PET/CT,PET/CT路径经验有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: 124I-evuzamitide is a pan-amyloid positron emission tomography (PET) radiotracer.

OBJECTIVES: The aim of this open-label study was to assess the performance and safety of 124I-evuzamitide PET/magnetic resonance imaging (MRI) in patients with known or suspected cardiac amyloidosis (CA).

METHODS: Consecutive patients with suspected or known CA were invited to participate in the trial and underwent imaging with 124I-evuzamitide (mean administered activity 1.05 ± 0.02 mCi), using PET/MRI preferentially and PET/computed tomography as an alternative. A positive scan was defined visually as tracer uptake in the left ventricular myocardium greater than blood pool activity by 3 expert readers. Equivocal scans were prespecified to be classified as negative (except for inter-reader agreement).

RESULTS: A total of 126 patients (mean age: 71.6 ± 10.6 years, 76.2% men) underwent 124I-evuzamitide PET/MRI (n = 123) or PET/CT (n = 3), of whom 87 (69%) received diagnoses of CA. All patients with CA had visually positive scans, and all patients without CA had visually negative scans by all 3 readers (100% sensitivity and specificity). There was disagreement on 5 patients, who were graded as having equivocal or negative scans (Fleiss's kappa = 0.94; none received a diagnosis of CA). Quantitatively, mean left ventricular/blood pool standardized uptake value ratio was 1.89 ± 0.29 and 0.91 ± 0.15 in patients with and without CA, respectively (P < 0.001). 124I-evuzamitide was well tolerated, without significant tracer-related adverse events.

CONCLUSIONS: 124I-evuzamitide PET provides excellent diagnostic accuracy in patients known or suspected to have CA and might provide a single upstream assessment for the presence or absence of CA. (Characterizing Iodine-124 Evuzumitide [AT-01] in Systemic Amyloidosis; NCT05758493).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Masri, Jahan, Gillan, et al. 124Iodine Evuzamitide Positron Emission Tomography in Patients With Established or Suspected Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2026. PMID: 42670739. doi:10.1016/j.jcmg.2026.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。